Correction to: Leukemia (2016) 30, 337–345; doi:10.1038/leu.2015.241; Published 10 November 2015
Following the publication of this article, the authors noted that the following Conflict of Interest statement was missing: EE, MJK and APK have a sponsored research agreement with Sanofi. AVO and CE are employees of Sanofi. All other authors declare no conflict of interest.
Additional information
The online version of the original article can be found at 10.1038/leu.2015.241
Rights and permissions
About this article
Cite this article
Thijssen, R., ter Burg, J., van Bochove, G. et al. Erratum: The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia 30, 1963 (2016). https://doi.org/10.1038/leu.2016.184
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.184
